PDCD1 and bladder transitional cell carcinoma: While the inhibition of PD-1/PD-L1 and Ephrin-related pathways has demonstrated promising outcomes in preclinical models (25), the expression pattern of Eph receptors and EFN ligands in most tumors, particularly BLCA, remains unclear, and their immunological roles are not well understood.